Advanced Search
MyIDEAS: Login

Under-Utilisation of beta-Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications

Contents:

Author Info

  • W. David Bradford

    (Department of Internal Medicine, Yale School Medicine, New Haven, Connecticut, USA)

  • Jersey Chen

    (Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine,New Haven, Connecticut, USA)

  • Harlan M. Krumholz

    (Connecticut Peer Review Organisation, Middletown, Connecticut, USA)

Abstract

We reviewed the literature on the efficacy and effectiveness of beta-blocker therapy and examined the economic consequences of under-utilisation. Despite the literature documenting the value of beta-blockers, the therapy is not prescribed at the appropriate rates. Approximately half of acute myocardial infarction (AMI) survivors who are eligible for the therapy do not receive it. There are 3 sources of costs that may arise from such under-utilisation: 1. increased morbidity and mortality associated with under-use 2. increased demand for related medical resources when the health state following an AMI is suboptimal due to under-use of beta-blocker therapy; and 3. increased cost due to substitution of higher cost and/or less effective treatments for beta-blockers. For the first category, there is evidence suggesting that around 2900 to 5000 lives are lost in the US in the first year following an AMI due to underprescription. There is very little evidence on the second category of costs; 1 recent study does address this issue and indicates that beta-blocker therapy can lead to a 22% relative risk reduction for hospital readmission during the first year. Several studies also show a decrease in reinfarction. There is no information that addresses the third category of costs adequately (though 1 study does present evidence of substitution of calcium channel-blockers for beta-blockers). We conclude that there is a dearth of evidence on the economic consequences of the under-utilisation of beta-blocker therapy. What does exist suggests that the net costs to society may be substantial.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-199915030-00005.pdf
Download Restriction: Pay per view

File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/fulltext.00019053-199915030-00005.htm
Download Restriction: Pay per view

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Bibliographic Info

Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

Volume (Year): 15 (1999)
Issue (Month): 3 ()
Pages: 257-268

as in new window
Handle: RePEc:wkh:phecon:v:15:y:1999:i:3:p:257-268

Contact details of provider:
Web page: http://pharmacoeconomics.adisonline.com/

Related research

Keywords: Reviews-on-treatment; Postmyocardial-infarction; Drug-utilisation; Beta-blockers; Prescribing; Cost-effectiveness; Guideline-utilisation; Mortality;

Find related papers by JEL classification:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:15:y:1999:i:3:p:257-268. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.